Mereo BioPharma MREO Stock
Mereo BioPharma Price Chart
Mereo BioPharma MREO Financial and Trading Overview
| Mereo BioPharma stock price | 2.31 USD |
| Previous Close | 1.78 USD |
| Open | 1.79 USD |
| Bid | 1.32 USD x 200 |
| Ask | 2.26 USD x 200 |
| Day's Range | 1.75 - 1.87 USD |
| 52 Week Range | 1.57 - 5.02 USD |
| Volume | 2.37M USD |
| Avg. Volume | 2.22M USD |
| Market Cap | 281.43M USD |
| Beta (5Y Monthly) | 0.345 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.55 USD |
MREO Valuation Measures
| Enterprise Value | 2.09B USD |
| Trailing P/E | N/A |
| Forward P/E | -59 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 4.68254 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -44.78 |
Trading Information
Mereo BioPharma Stock Price History
| Beta (5Y Monthly) | 0.345 |
| 52-Week Change | -55.52% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 5.02 USD |
| 52 Week Low | 1.57 USD |
| 50-Day Moving Average | 2.44 USD |
| 200-Day Moving Average | 3.02 USD |
MREO Share Statistics
| Avg. Volume (3 month) | 2.22M USD |
| Avg. Daily Volume (10-Days) | 7.32M USD |
| Shares Outstanding | 159M |
| Float | 508.72M |
| Short Ratio | 6.64 |
| % Held by Insiders | 0.96% |
| % Held by Institutions | 76.57% |
| Shares Short | 7.96M |
| Short % of Float | 7.04% |
| Short % of Shares Outstanding | 5.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -47.59% |
| Return on Equity (ttm) | -91.70% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -46733000 USD |
| Net Income Avi to Common (ttm) | -47189000 USD |
| Diluted EPS (ttm) | -0.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 62.48M USD |
| Total Cash Per Share (mrq) | 0.08 USD |
| Total Debt (mrq) | 747K USD |
| Total Debt/Equity (mrq) | 1.24 USD |
| Current Ratio (mrq) | 8.923 |
| Book Value Per Share (mrq) | 0.378 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33172000 USD |
| Levered Free Cash Flow (ttm) | -20503124 USD |
Profile of Mereo BioPharma
| Country | United States |
| State | N/A |
| City | London |
| Address | One Cavendish Place |
| ZIP | W1G 0QF |
| Phone | 44 33 3023 7300 |
| Website | https://www.mereobiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 36 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Q&A For Mereo BioPharma Stock
What is a current MREO stock price?
Mereo BioPharma MREO stock price today per share is 2.31 USD.
How to purchase Mereo BioPharma stock?
You can buy MREO shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mereo BioPharma?
The stock symbol or ticker of Mereo BioPharma is MREO.
Which industry does the Mereo BioPharma company belong to?
The Mereo BioPharma industry is Biotechnology.
How many shares does Mereo BioPharma have in circulation?
The max supply of Mereo BioPharma shares is 159.13M.
What is Mereo BioPharma Price to Earnings Ratio (PE Ratio)?
Mereo BioPharma PE Ratio is now.
What was Mereo BioPharma earnings per share over the trailing 12 months (TTM)?
Mereo BioPharma EPS is -0.25 USD over the trailing 12 months.
Which sector does the Mereo BioPharma company belong to?
The Mereo BioPharma sector is Healthcare.
Mereo BioPharma MREO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23593.1 USD — |
-0.09
|
4.43B USD — | 23567.86 USD — | 23665.15 USD — | — - | 4.43B USD — |
| US Tech Global Market Composite NQGM | 2322.44 USD — |
-1.01
|
— — | 2316.74 USD — | 2339.59 USD — | — - | — — |
| US Tech Biotechnology NBI | 5809.25 USD — |
-0.59
|
— — | 5792.54 USD — | 5835.34 USD — | — - | — — |
| US Tech Health Care IXHC | 1206.13 USD — |
-0.49
|
— — | 1203.49 USD — | 1210.54 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}